Xylem’s fourth quarter results were driven by disciplined execution and operational improvements across its portfolio, though the market reacted negatively due to concerns about future growth.
Xavier Musca and Frédéric Oudéa having indicated their desire not to seek reappointment1, the Board of Directors warmly thanked them for their respective contributions to the work of the Board of ...
Victoire GruxTel.: +33 6 04 52 16 55victoire.grux@capgemini.com Investor relations:Vincent BiraudTel.: +33 1 47 54 50 87vincent.biraud@capgemini.com Change in the composition of Capgemini's ...
The stock was sluggish on the back of Xylem Inc.'s (NYSE:XYL) recent earnings report. Our analysis suggests that there are some reasons for hope that investors should be aware of. AI is about to ...
A stone wall deep inside a Greek cave stands as the oldest known human made structure. Dated to 23,000 years ago, it predates Egypt's Great Pyramid by over 18,000 years. In 2025, after nearly a decade ...
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs ...
Xylem, Inc. engages in the design, manufacture, and application of engineered technologies for the water industry. It operates through the following business segments: Water Infrastructure, Applied ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results